MiNK Therapeutics, Inc. (INKT)

NASDAQ: INKT · IEX Real-Time Price · USD
2.61
+0.03 (1.16%)
Nov 29, 2022 3:06 PM EDT - Market open
1.16%
Market Cap 87.17M
Revenue (ttm) n/a
Net Income (ttm) -25.99M
Shares Out 33.76M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,543
Open 2.53
Previous Close 2.58
Day's Range 2.5 - 2.65
52-Week Range 1.09 - 14.54
Beta n/a
Analysts Buy
Price Target 8.93 (+248.8%)
Earnings Date Dec 5, 2022

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based... [Read more]

Industry Biotechnology
IPO Date Oct 15, 2021
Employees 33
Stock Exchange NASDAQ
Ticker Symbol INKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for INKT stock is "Buy." The 12-month stock price forecast is 8.93, which is an increase of 248.83% from the latest price.

Price Target
$8.93
(248.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

1 week ago - GlobeNewsWire

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) --  MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf...

2 weeks ago - GlobeNewsWire

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

-  Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting -  R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast

3 weeks ago - GlobeNewsWire

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET

1 month ago - GlobeNewsWire

MiNK Therapeutics to Host R&D Event November 10, 2022

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

1 month ago - GlobeNewsWire

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

1 month ago - GlobeNewsWire

MiNK Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

2 months ago - GlobeNewsWire

MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

3 months ago - GlobeNewsWire

MiNK Therapeutics to Participate at BTIG Biotechnology Conference

NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf,...

3 months ago - GlobeNewsWire

MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update

Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET

4 months ago - GlobeNewsWire

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, ...

6 months ago - GlobeNewsWire

MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, ...

6 months ago - GlobeNewsWire

MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf...

7 months ago - GlobeNewsWire

MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

NEW YORK, March 18, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...

8 months ago - GlobeNewsWire

MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf...

8 months ago - GlobeNewsWire

MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, inva...

8 months ago - GlobeNewsWire

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

10 months ago - GlobeNewsWire

MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

1 year ago - GlobeNewsWire

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with Ag...

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

1 year ago - GlobeNewsWire

MiNK Therapeutics Announces Closing of Initial Public Offering

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

1 year ago - GlobeNewsWire

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-s...

1 year ago - GlobeNewsWire